logo-loader
viewOpen Orphan PLC

Open Orphan's Cathal Friel details new £3.5mln RSV study agreement

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study.

He says the contract is projected to deliver £3.5mln in revenue all of which is expected to be recognised in 2020.

Quick facts: Open Orphan PLC

Price: 13.2475 GBX

AIM:ORPH
Market: AIM
Market Cap: £88.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan PLC - Proactive One2One Virtual Event

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to investors at the Proactive One2One Virtual Event. Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

5 days, 2 hours ago

2 min read